Advertisement

Topics

GSK Japan Selects Platform to Boost Pharmacovigilance Activities

05:45 EDT 1 Sep 2017 | PharmPro

GlaxoSmithKline Japan selects SciBite Semantic Platform to enhance pharmacovigilance capabilities. A Proof of Concept was initiated in order to assess whether the technology had the potential to complement current Japanese pharmacovigilance processes.
Contributed Author: 
SciBite
Topics: 

Original Article: GSK Japan Selects Platform to Boost Pharmacovigilance Activities

NEXT ARTICLE

More From BioPortfolio on "GSK Japan Selects Platform to Boost Pharmacovigilance Activities"

Quick Search
Advertisement
 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...